Efficient and easy synthesis of new Benzohchromene and Benzohquinoline derivatives as a new class of cytotoxic agents
Publication date: Available online 22 May 2019Source: Journal of Molecular StructureAuthor(s): Mogedda E. Haiba, Ebtehal S. Al-Abdullah, Nesreen S. Ahmed, Hazem A. Ghabbour, Hanem M. AwadAbstractThe present study presents easy and rapid methods to synthesize new benzo[h]chromene and benzo[h] quinoline derivatives. Cytotoxic evaluations of most of the examined compounds indicated that they had significant cytotoxic activities against HepG-2 (human cancer cells) and MCF-7 (breast cancer cells). Compounds 4 and 11 had stronger cytotoxic activity against HepG-2 human cancer cells than the reference drug Doxorubicin. All the examined compounds were significantly active against MCF-7 human cancer cells and were more potent than Doxorubicin. The structures of the new compounds were established from their spectral and elemental data. In addition the structures of benzo[h] chromene 3 and benzo[h]quinoline 7 were recognized by x-ray crystallography. Herein detailed syntheses, spectroscopic information and biological actions of the tested compounds are reported.
We report the application of RNA sequencing technology for high-throughput profiling of mRNA expression in breast cancer cell line
The original version of this article unfortunately contained a mistake in the article title. The captured title was “Local-Regional Evaluation and Therapy (D Euhus, Section Editor)” instead of “Ablative Treatment of Breast Cancer; Are We There Yet?”
Findings seen among pre - /perimenopausal survivors of stage 0 to III breast cancer
Condition: Hormone Receptor Positive Metastatic Breast Cancer Intervention: Other: Exercise Treatment Sponsor: Memorial Sloan Kettering Cancer Center Recruiting
Condition: Metastatic Breast Cancer Interventions: Drug: Abemaciclib; Drug: Nonsteroidal Aromatase Inhibitor (NSAI) Sponsor: Eli Lilly and Company Not yet recruiting
Condition: Breast Cancer Interventions: Drug: Pembrolizumab; Drug: Trastuzumab Biosimilar ABP 980; Drug: Pertuzumab Sponsors: West German Study Group; Merck Sharp & Dohme Corp.; Amgen; NanoString Technologies, Inc. Not yet recruiting
MONDAY, June 17, 2019 -- Higher soy consumption is linked to fewer osteoporotic fractures in younger breast cancer survivors, according to a study published online May 21 in JNCI Cancer Spectrum. Neil Zheng, from Yale University in New Haven,...
MONDAY, June 17, 2019 -- Among black women in the United States, the prevalence of triple-negative breast cancer varies by birthplace, according to a study published online June 13 in Cancer. Hyuna Sung, Ph.D., from the American Cancer Society in...